Postmarket study of Sebacia Microparticles treatment during adoption into clinical use for patients with mild to moderate inflammatory acne vulgaris.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
125
Sebacia Microparticles procedure involving microparticles and 1064 nm laser. Three treatment procedures over a two-week period.
Miami Dermatology & Laser Institute
Miami, Florida, United States
Dermatology Institute of Boston
Boston, Massachusetts, United States
International Clinical Research
Murfreesboro, Tennessee, United States
Austin Institute for Clinical Research - Central
Austin, Texas, United States
Inflammatory Lesion Count
Percent change in number of inflammatory lesions from baseline
Time frame: Months 2, 3, 6, 9 and 12
Investigator's Global Assessment
Percent of subjects clear (IGA 0) or almost clear (IGA 1)
Time frame: Months 2, 3, 6, 9 and 12
Physician's Overall Assessment of Improvement
Categorical improvement from baseline (worse, no change, minimal, moderate, marked, complete)
Time frame: Months 2, 3, 6, 9 and 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Austin Institute for Clinical Research - Pflugerville
Pflugerville, Texas, United States
Premier Clinical Research
Spokane, Washington, United States